KAREN J WILSON
CIK 1267490 · SVP, Finance & PAO · last filed 2026-06-22
KAREN J WILSON is a SVP, Finance & PAO who has filed 59 SEC Form 4 insider transactions across 7 companies since 2009. The most recent filing, for SER, was dated Jun 22, 2026. Across all open-market trades the lifetime net is −$11.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $4.8M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$4.81M
7
59
-$11.47M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SER | Director | 30,100 | $2.05 | $61.7K | $54.7K | 5 | 2026-06-22 |
| LAVA Therapeutics NV (LVTX) Delisted | Director | 0 | $1.74 | $0 | $0 | 2 | 2025-11-17 |
| ELTX | Director | — | $2.89 | — | $0 | 3 | 2025-05-20 |
| Elicio Therapeutics, Inc. (ANGN) Delisted | Director | 1,872 | $10.00 | $18.7K | $0 | 3 | 2022-06-13 |
| Vaxart, Inc. (VXRT) Delisted | Director | — | $0.32 | — | $0 | 2 | 2021-06-17 |
| JAZZ | SVP, Finance & PAO | 18,385 | $258.05 | $4.74M | -$11.52M | 43 | 2019-03-07 |
| PDL BIOPHARMA, INC. (PDLI) Delisted | VP of Finance & PAO | 10,494 | — | — | $0 | 1 | 2009-05-11 |
Recent Filings
59 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-22 | SER | Grant (A) | — | $0 | EDGAR |
| 2026-06-15 | SER | Buy (P) | +10,100 | $17.7K | EDGAR |
| 2026-05-26 | SER | Buy (P) | +20,000 | $37.0K | EDGAR |
| 2025-11-17 | LAVA Therapeutics NV (LVTX) Delisted | Disp (D) | −10,000 | $0 | EDGAR |
| 2025-11-10 | SER | Grant (A) | — | $0 | EDGAR |
| 2025-05-20 | ELTX | Grant (A) | — | $0 | EDGAR |
| 2025-02-18 | LAVA Therapeutics NV (LVTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-01-15 | SER | Grant (A) | — | $0 | EDGAR |
| 2024-11-25 | ELTX | Grant (A) | — | $0 | EDGAR |
| 2023-12-29 | ELTX | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.